In collaboration with the Department of Neurology and the Metabolomics Department, the project is investigating metabolic products in cerebrospinal fluid in order to identify biomarkers for CNS infections and cell damage and to distinguish long COVID and viral from autoimmune diseases.
This project focuses on lung infections such as influenza, COVID-19, pneumonia and tuberculosis in order to improve diagnostics, patient stratification and therapy. RNA molecules and metabolites are being investigated as biomarkers and complementary therapies.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
Liu Z, Crișan T, Qi C, Gupta M, Liu X, Moorlag S, Koeken V, de Bree L, Mourits V, Gao X, Baccarelli A, Schwartz J, Pessler F, Guzmán C, Li Y, Netea M, Joosten L, Xu C
de Araujo L, Ribeiro-Alves M, Wipperman M, Vorkas C, Pessler F, Saad M
Sohail A, Waqas F, Braubach P, Czichon L, Samir M, Iqbal A, de Araujo L, Pleschka S, Steinert M, Geffers R, Pessler F
Previously unknown effects of citraconic acid described
Read more
TWINCORE researchers describe a mechanism that inhibits virus replication and protects cells from damage. Interestingly, a drug that has already been approved could prove useful in combating various viruses.
Read moreDouble effect of the body's own signalling molecule itaconic acid described
Read more